Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | The value of treating MGUS and smoldering myeloma patients with novel immunotherapies

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, briefly explains the importance of using the best available drugs at an earlier stage instead of waiting until disease progression. Dr Ghobrial also highlights the excitement around immunotherapies, including CAR-T therapy and antibodies, for the treatment of patients with smoldering myeloma and monoclonal gammopathy of undetermined significance (MGUS). This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.